Page last updated: 2024-12-07
pseudoisocytidine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
pseudoisocytidine: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 124345 |
| SCHEMBL ID | 713634 |
| MeSH ID | M0059590 |
Synonyms (21)
| Synonym |
|---|
| 57100-18-2 |
| 2-amino-5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1h-pyrimidin-4-one |
| pseudoisocytidine |
| 4-(1h)-pyrimidinone, 2-amino-5-.beta.-d-ribofuranosyl- |
| 59464-15-2 |
| nsc279852 |
| 2-amino-5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrimidin-6-one |
| AKOS015919923 |
| 4(1h)-pyrimidinone, 2-amino-5-beta-d-ribofuranosyl- |
| tdh73l8xqd , |
| psi-isocytidine |
| 5-(beta-d-ribofuranosyl)isocytosine |
| unii-tdh73l8xqd |
| 4(1h)-pyrimidinone, 2-amino-5-.beta.-d-ribofuranosyl- |
| 5-(.beta.-d-ribofuranosyl)isocytosine |
| SCHEMBL713634 |
| 4(1h)-pyrimidinone,2-amino-5-b-d-ribofuranosyl- |
| DTXSID20205717 |
| AKOS025396670 |
| Q15632736 |
| A869762 |
Research Excerpts
Overview
Pseudoisocytidine (psi ICyd) is a C-nucleoside with enhanced stability and resistance to enzymatic deamination.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Pseudoisocytidine (psi ICyd) is a C-nucleoside with enhanced stability and resistance to enzymatic deamination when compared to 5-azacytidine and 1-beta-D-arabinofuranosylcytosine. " | ( Biochemical, pharmacological, and phase I clinical evaluation of pseudoisocytidine. Burchenal, JH; Chou, TC; Philips, FS; Sternberg, SS; Tan, CT; Woodcock, TM; Young, CW, 1980) | 1.94 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " NBMPR-P and other inhibitors of nucleoside transport may have therapeutic applications in manipulation of the pharmacokinetic behavior and toxicity of nucleoside drugs." | ( Modification by nitrobenzylthioinosine-5'-monophosphate of pseudoisocytidine pharmacokinetics in mice and rats through inhibition of membrane transport. Chou, TC; Kolassa, N; Paterson, AR, 1983) | 0.51 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (10)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 7 (70.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.87
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.87) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (10.00%) | 5.53% |
| Reviews | 1 (10.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||